<?xml version="1.0" encoding="UTF-8"?><html xmlns="http://www.w3.org/1999/xhtml" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:protege="http://protege.stanford.edu/plugins/owl/protege#" xmlns:xsp="http://www.owl-ontologies.com/2005/08/07/xsp.owl#" xmlns:Thesaurus="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#" xmlns:owl="http://www.w3.org/2002/07/owl#" xmlns:xsd="http://www.w3.org/2001/XMLSchema#" xmlns:rdfs="http://www.w3.org/2000/01/rdf-schema#" xmlns:dublincorens="http://purl.org/dc/elements/1.1/"  version="XHTML+RDFa 1.0" ><body>Tan et al. Molecular Cancer 2014, 13:13 <br /> http://www.molecular-cancer.com/content/13/1/13 <br />  <br />  <br />  <br />  <br />  RESEARCH                                                                                                                                      Open Access <br />  <br /> Bosutinib inhibits migration invasion ack1 <br /> in kras mutant non-small cell lung cancer <br /> Daniel SW Tan1,2, Benjamin Haaland3,4, Jia Min Gan5, Su Chin Tham5,10, Indrajit Sinha6, Eng Huat Tan1, Kiat Hon Lim7, <br /> Angela Takano7, Sai Sakktee Krisna1,2, Minn Minn Myint Thu7, Hoe Peng Liew8, Axel Ullrich9, Wan-Teck Lim1,3,10 <br /> and Boon Tin Chua5,10* <br />  <br />  <br />   <span id='am-1' about='protege:abstract' typeof='owl:Thing'>Abstract</span> <br />   The advent effective targeted therapeutics led increasing emphasis precise biomarkers accurate patient <br />   stratification. Here, role ACK1, non-receptor tyrosine kinase abrogating migration invasion <br />   KRAS mutant lung adenocarcinoma. Bosutinib, inhibits ACK1 2.7 nM IC50, inhibit cell migration <br />   invasion viability panel non-small cell lung cancer (NSCLC) cell lines. Knockdown ACK1 abrogated <br />   bosutinib-induced inhibition cell migration invasion specifically KRAS mutant cells. This finding further <br />   confirmed in vivo zebrafish metastatic model. Tissue microarray data 210 Singaporean lung adenocarcinomas <br />   indicate cytoplasmic ACK1 significantly over-expressed relative paired adjacent non-tumor tissue. Interestingly, <br />   ACK1 expression &#226;&#8364;&#339;normal&#226;&#8364;? tissue adjacent tumour, tumour, independently associated poor overall <br />   relapse-free <span id='am-6' about='Thesaurus:TESSE01' typeof='owl:Thing'><span id='am-7' property="Thesaurus:code" content="TEESS15" datatype="rdf:PlainLiteral"></span><span id='am-8' property="rdfs:label" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-9' property="Thesaurus:Preferred_Name" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-10' property="Thesaurus:code" content="TEESS24" datatype="rdf:PlainLiteral"></span><span id='am-11' property="Thesaurus:code" content="TEESS21" datatype="rdf:PlainLiteral"></span><span id='am-12' property="Thesaurus:code" content="TEESS13" datatype="rdf:PlainLiteral"></span><span id='am-13' property="Thesaurus:code" content="TEESS04" datatype="rdf:PlainLiteral"></span><span id='am-14' property="rdfs:label" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-15' property="Thesaurus:Preferred_Name" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-16' property="rdfs:label" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-17' property="Thesaurus:code" content="TEESS03" datatype="rdf:PlainLiteral"></span><span id='am-18' property="rdfs:label" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-19' property="Thesaurus:code" content="TEESS10" datatype="rdf:PlainLiteral"></span><span id='am-20' property="Thesaurus:Preferred_Name" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-21' property="Thesaurus:Preferred_Name" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-22' property="Thesaurus:Preferred_Name" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-23' property="rdfs:label" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-24' property="Thesaurus:code" content="TEESS23" datatype="rdf:PlainLiteral"></span><span id='am-25' property="Thesaurus:Preferred_Name" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-26' property="Thesaurus:code" content="TEESS16" datatype="rdf:PlainLiteral"></span><span id='am-27' property="Thesaurus:Preferred_Name" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-28' property="Thesaurus:code" content="TEESS05" datatype="rdf:PlainLiteral"></span><span id='am-29' property="Thesaurus:code" content="TEESS22" datatype="rdf:PlainLiteral"></span><span id='am-30' property="Thesaurus:Preferred_Name" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-31' property="rdfs:label" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-32' property="Thesaurus:Preferred_Name" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-33' property="Thesaurus:code" content="TEESS12" datatype="rdf:PlainLiteral"></span><span id='am-34' property="Thesaurus:Preferred_Name" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-35' property="rdfs:label" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-36' property="Thesaurus:code" content="TEESS02" datatype="rdf:PlainLiteral"></span><span id='am-37' property="rdfs:label" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-38' property="Thesaurus:Preferred_Name" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-39' property="Thesaurus:Preferred_Name" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-40' property="Thesaurus:Preferred_Name" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-41' property="rdfs:label" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-42' property="Thesaurus:code" content="TEESS11" datatype="rdf:PlainLiteral"></span><span id='am-43' property="Thesaurus:Preferred_Name" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-44' property="rdfs:label" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-45' property="Thesaurus:Preferred_Name" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-46' property="Thesaurus:Preferred_Name" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-47' property="Thesaurus:Preferred_Name" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-48' property="rdfs:label" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-49' property="rdfs:label" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-50' property="Thesaurus:code" content="TEESS18" datatype="rdf:PlainLiteral"></span><span id='am-51' property="Thesaurus:code" content="TEESS25" datatype="rdf:PlainLiteral"></span><span id='am-52' property="Thesaurus:Preferred_Name" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-53' property="Thesaurus:code" content="TEESS19" datatype="rdf:PlainLiteral"></span><span id='am-54' property="rdfs:label" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-55' property="Thesaurus:code" content="TEESS08" datatype="rdf:PlainLiteral"></span><span id='am-56' property="Thesaurus:code" content="TEESS09" datatype="rdf:PlainLiteral"></span><span id='am-57' property="Thesaurus:code" content="TEESS17" datatype="rdf:PlainLiteral"></span><span id='am-58' property="rdfs:label" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-59' property="Thesaurus:Preferred_Name" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-60' property="Thesaurus:code" content="TEESS01" datatype="rdf:PlainLiteral"></span><span id='am-61' property="Thesaurus:Preferred_Name" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-62' property="Thesaurus:Preferred_Name" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-63' property="rdfs:label" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-64' property="Thesaurus:Preferred_Name" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-65' property="rdfs:label" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-66' property="Thesaurus:Preferred_Name" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-67' property="Thesaurus:code" content="TEESS07" datatype="rdf:PlainLiteral"></span><span id='am-68' property="rdfs:label" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-69' property="rdfs:label" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-70' property="rdfs:label" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-71' property="rdfs:label" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-72' property="Thesaurus:code" content="TEESS06" datatype="rdf:PlainLiteral"></span><span id='am-73' property="Thesaurus:Preferred_Name" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-74' property="rdfs:label" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-75' property="rdfs:label" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-76' property="rdfs:label" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-77' property="Thesaurus:Preferred_Name" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-78' property="rdfs:label" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-79' property="rdfs:label" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-80' property="rdfs:label" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-81' property="Thesaurus:code" content="TEESS14" datatype="rdf:PlainLiteral"></span><span id='am-82' property="Thesaurus:Preferred_Name" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-83' property="Thesaurus:code" content="TEESS20" datatype="rdf:PlainLiteral"></span>survival</span>. In conclusion, inhibition ACK1 bosutinib attenuates migration invasion the <br />   context KRAS mutant NSCLC fulfil therapeutic niche combinatorial treatment approaches. <br />   Keywords: Lung cancer, ACK1, KRAS, Bosutinib, Metastasis <br />  <br />  <br /> Introduction                                                                        domains CRIB Cdc42 binds [4]. The <br /> Lung cancer leading cause cancer related death                            C-terminal half protein interacts partners <br /> world-wide [1]. It estimated ~228 190 new                          including clathrin, EGFR, ubiquitin, Nedd4 E3 ligase and <br /> lung cancer cases ~159 480 lung cancer deaths                                Grb2 [5-8]. Recent work Mahajan et al. shows that <br /> the United States 2012 (http://seer.cancer.gov/statfacts/                        ACK1 phosphorylates AKT Tyr 176, resulting its <br /> html/lungb.html). Although increasing number gen-                             activation [9]. Several reports implicated ACK1 <br /> etic alterations non-small cell lung cancer (NSCLC)                              over-expression amplification tumorigenesis of <br /> have amenable targeted therapeutics [2],                               different tissue types e.g. gastric, pancreatic lung <br /> emerging challenge identification co-factors                              [10,11]. High expression phosphorylated ACK1 cor- <br /> that modulate attenuate intracellular signaling                             relates disease progression breast, prostate and <br /> cascades implicated drug response resistance&#226;&#8364;&#8220;so                               pancreatic cancers [12-14], specific interactions <br /> as enable better patient selection rational drug                             ACK1 kinase key signaling nodes e.g. <br /> combinations [3].                                                                   androgen receptors prostate cancer. In melanoma <br />   Activated Cdc42 associated kinase (ACK1) non-                                cell lines, ACK1 activated response integrin sig- <br /> receptor tyrosine kinase residing cytoplasm. The                             naling, resulting cell spreading [15]. In vivo, ACK1 <br /> kinase domain located N-terminal half                              over-expressing cells resulted aggressive metastatic <br /> protein followed multiple protein-protein interaction                            tumors [10,12] vitro silencing ACK1 gene <br />                                                                                     RAS-transformed NIH3T3 cells increased apoptosis <br />                                                                                     [16]. Recently, shown silencing ACK1 <br /> * Correspondence: btchua@imcb.a-star.edu.sg <br /> 5 <br />  Singapore OncoGenome Laboratory, Institute Medical Biology, Agency of <br />                                                                                     results reduced ERK AKT phosphorylation and <br /> Science Technology Research, Singapore, Singapore                               interestingly, EMT reversion [17]. <br /> 10 <br />   INM-SOG, Institute Molecular Cell Biology, Agency Science                 We hypothesized ACK1 hyperactivity through <br /> Technology Research, Singapore, Singapore <br /> Full list author information available end article <br />                                                                                     over-expression influences metastatic potential lung <br />  <br />                                       &#194;&#169; 2014 Tan et al.; licensee BioMed Central Ltd. This Open Access article distributed terms Creative <br />                                       Commons Attribution License (http://creativecommons.org/licenses/by/2.0), permits unrestricted use, distribution, and <br />                                       reproduction medium, provided original work properly cited. The Creative Commons Public Domain Dedication <br />                                       waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies data available article, unless otherwise <br />                                       stated. <br />  Tan et al. Molecular Cancer 2014, 13:13                                                                           Page 2 10 <br /> http://www.molecular-cancer.com/content/13/1/13 <br />  <br />  <br />  <br />  <br /> adenocarcinoma targeted kinase inhibitors.       Bosutinib inhibition cell migration invasion is <br /> Bosutinib (SKI-606) generation dual SRC-ABL           ACK1 dependent SRC-independent <br /> kinase inhibitor developed Wyeth (Pfizer) binds     Since SRC ACK1 play role cell motility <br /> and prevents auto-phosphorylation ACK1 IC50             [17,21-24] bosutinib inhibit kinases, we <br /> 2.7 nM [18,19]. Our results bosutinib inhibited        evaluated target kinases (ACK1 <br /> cancer cell migration invasion ACK-1 KRAS           SRC) mediating migratory effect. Using <br /> dependent manner &#226;&#8364;&#8220; in vitro cell lines        NCI-H1792, KRAS mutated NSCLC cell, silenced <br /> an vivo zebrafish model. Further, validated ACK1           ACK1 SRC measured migration <br /> protein expression 210 lung adenocarcinoma tissue             invasion bosutinib treatment. Real time PCR <br /> microarrays using immunohistochemistry, high               data (Figure 3A) showed silencing ACK1, SRC or <br /> expression tumor ACK1 observed compared                effectively reduced respective transcript levels. <br /> <span id='am-5' about='protege:TO' typeof='owl:Thing'>to</span> paired adjacent &#226;&#8364;&#339;normal&#226;&#8364;? lung tissue. Although tumor          Expectedly, ACK1 SRC knockdown, cell migration <br /> ACK1 expression associated survival out-            invasion reduced ~50%, consolidating the <br /> comes resected NSCLC, intriguingly, ACK1 expression           role kinases cell motility (Figure 3B &amp; C). In <br /> in adjacent &#226;&#8364;&#339;normal&#226;&#8364;? lung associated worse              SRC-silenced cells, dose-dependent inhibition cell mi- <br /> overall relapse-free survival univariate         gration invasion observed treatment <br /> multivariate models.                                             increasing concentration bosutinib. In contrast, <br />                                                                  ACK1 ACK1/SRC dual-silenced cells, bosutinib- <br />                                                                  induced inhibition cell migration abolished. The <br /> Results <br />                                                                  effect observed second KRAS mutant <br /> Bosutinib inhibits KRAS mutant KRAS wild type <br />                                                                  NSCLC cell line, SK-Lu-1 (Additional file 1: Figure S1) <br /> cell migration invasion <br />                                                                  treated bosutinib. These data support role of <br /> We previously demonstrated ACK1 plays an <br />                                                                  ACK1 target bosutinib inhibiting cell migration <br /> important role cell migration epithelial mesenych- <br />                                                                  invasion KRAS mutant cell lines. <br /> mal transition in vitro over-expression gene <br /> silencing systems [17]. We tested effect bosutinib <br />                                                                  Reduction lung cancer cell metastasis zebrafish <br /> on cell migration panel NSCLC cell lines that <br />                                                                  embryos bosutinib ACK1 dependent <br /> migrate efficiently 8 &#206;&#188;m transwell 10% FBS <br />                                                                  Next, examined vitro migratory invasive <br /> as chemoattractant. We tested invasive potential <br />                                                                  inhibition bosutinib translated metastasis <br /> of cell lines using Matrigel&#226;&#8222;&#162; assay. As shown Figure 1, <br />                                                                  inhibition vivo. Zebrafish well-recognized model of <br /> sub-lethal concentration (0.1, 0.5 1 &#206;&#188;M) bosutinib <br />                                                                  human malignancy conserved genetics cell <br /> were sufficient inhibit cell migration invasion a <br />                                                                  biology [25]. Using zebrafish host organism, we <br /> dose-dependent manner. Unexpectedly, ob- <br />                                                                  developed quantitative vivo cell migration assay <br /> served KRAS mutant cells shown Figure 1A and <br />                                                                  monitor response cells anti-cancer agents. <br /> C. In contrast, bosutinib effect migration 3 <br />                                                                  Transparency embryos provides unique <br /> out 4 KRAS wild type NSCLC cell lines (Figure 1B). In <br />                                                                  ability visualize vivo drug responses migratory <br /> addition, 4 KRAS mutant cell lines showed reduced <br />                                                                  changes cancer cells real time. Here injected <br /> migration invasion Matrigel assay, KRAS <br />                                                                  boluses fluorescently labeled human NCI-H2009 cells, <br /> WT cell lines tested inhibited bosutinib <br />                                                                  successfully transfected siRNA against <br /> (Figure 1D). <br />                                                                  ACK1, SRC negative control (Additional file 2: Figure <br />                                                                  S2), yolk sac 24&#226;&#8364;&#8220;30 h old embryos. The labeled <br /> Effect bosutinib viability NSCLC cell lines          NCI-H2009 cells observed migrate the <br /> independent KRAS status                                       injection site metastasized various parts em- <br /> Across panel NSCLC lines, bosutinib reduced cell          bryos (Figure 4A). To test effect bosutinib these <br /> viability micromolar IC50 1&#226;&#8364;&#8220;5 &#206;&#188;M (Figure 2A        metastatic cells vivo, pretreated labeled cells <br /> and B) apoptosis (Figure 2C) tested KRAS              bosutinib injecting embryos. <br /> mutant KRAS wild type (WT) lung cancer cell lines.           The metastatic potential NCI-H2009 cells transfected <br /> Based steady state (D15) dosing bosutinib [MW              control SRC siRNA significantly reduced after <br /> 530.44616] clinic 400 500 mg daily, Cmax           pretreatment low dose bosutinib (Figure 4A B) <br /> was 190 ng/mL 273 ng/mL respectively, [20] ap-               significant reduction observed in <br /> proximately corresponding vitro concentrations             cells transfected ACK1 siRNA (Figure 4C). These <br /> of 0.3 &#226;&#8364;&#8220; 0.5 &#206;&#188;M. Thus, clinically relevant doses bosuti-      observations support role ACK1 target <br /> nib able inhibit migration invasion           bosutinib inhibiting cell migration invasion in <br /> viability NSCLC cell lines.                                   KRAS mutant cell lines vivo. <br />  Tan et al. Molecular Cancer 2014, 13:13                                                                                              Page 3 10 <br /> http://www.molecular-cancer.com/content/13/1/13 <br />  <br />  <br />  <br />  <br />  Figure 1 Bosutinib inhibit KRAS mutant cell migration invasion KRAS wildtype cells. The serum-starved KRAS (A &amp; C) mutant <br />  (B &amp; D) wildtype cells trypsinized seeded upper chamber Transwell (8 mm pore, A &amp; B) Matrigel&#226;&#8222;&#162; (C &amp; D), the <br />  presence DMSO bosutinib various concentrations (0.1, 0.5 1 &#206;&#188;M). Medium containing 10% FBS DMSO bosutinib (0.1, 0.5 and <br />  1 &#206;&#188;M) used chemoattractant lower chamber. The migrated invaded cells fixed stained 0.5% crystal violet blue after <br />  6 h 24 h respectively. Cells migrated invaded filter counted. Experiments carried duplicates five <br />  random fields counted. The percentage migrated invaded cells expressed respect DMSO treated cells. <br />  <br />  <br /> ACK1 highly expressed lung adenocarcinoma                            paired surrounding non-tumor &#226;&#8364;&#339;normal&#226;&#8364;? tissue in- <br /> In 2005, Van der Horst et al. [10] showed ACK1                    dependently associated worse overall relapse-free <br /> gene amplified numerous cancer types including lung                  survival, shown Table 1. <br /> cancers correlated metastatic potential and <br /> poor prognosis. Here, validated total protein ex-                   Discussion <br /> pression ACK1 using immunohistochemistry staining                       In era molecularly-directed therapeutics NSCLC, <br /> on 210 lung adenocarcinoma in-house tissue                           increasing discovery novel <br /> microarray (TMA). In comparison surrounding paired                    biomarkers improved patient stratification treat- <br /> non-tumor lung sections, ACK1 substantially signifi-                ment. While EGFR mutant ALK translocated NSCLC <br /> cantly (all p &lt; 0.001) over-expressed tumor tissue               successfully targeted clinic, KRAS muta- <br /> immunohistochemisty summaries (including ACK1 max-                         tions account 15-22% cases date, no <br /> imum staining intensity, percentage staining, IP). The                 clinically validated targeted therapies [2,26]. In article, <br /> difference IP score (see Immunohistochemistry section                   present novel data highlighting potential therapeutic <br /> in Method <span id='am-3' about='Thesaurus:DEFINITION' typeof='owl:Thing'>definition</span>) tumour adjacent                      role bosutinib abrogating migration invasion in <br /> non-tumour lung tissue illustrated Figure 5.                         KRAS mutant NSCLC cell lines ACK1. <br />                                                                               The unexpected observation bosutinib-mediated at- <br /> ACK1 over-expression adjacent &#226;&#8364;&#339;normal&#226;&#8364;? lung tissue                      tenuation migration invasion specifically KRAS <br /> portends poorer outcomes lung adenocarcinoma                            mutant cell lines underscores importance evaluating <br /> The ACK1 IHC data subjected statistical analysis.                   targeted therapeutics appropriate genetic context. <br /> Here, significant univariates predicted                  Our experiments reveal potential identifying <br /> overall relapse-free survival stage, grade, smoking               therapeutic niches oncogenic drivers, &#226;&#8364;&#339;off- <br /> status, histology, non-tumor ACK1 expression,                       target&#226;&#8364;? inhibition selected kinases confer desirable <br /> shown supplementary data, Additional file 3: Table S1.                  anti-cancer effects reducing cell viability or <br /> Multivariate models developed, adjusting                      induction apoptosis. Indeed, induction apoptosis <br /> relationship prognosis important clinical                  bosutinib doses 1 &#206;&#188;M likely involves non- <br /> covariates stage grade, context Cox propor-                specific multi-kinase inhibition. In contrast, inhibition of <br /> tional hazards model. Interestingly, ACK1 over-expression                  migration invasion observed doses low as <br />  Tan et al. Molecular Cancer 2014, 13:13                                                                                                     Page 4 10 <br /> http://www.molecular-cancer.com/content/13/1/13 <br />  <br />  <br />  <br />  <br />  Figure 2 Effect bosutinib viability NSCLC cell lines independent KRAS status. The KRAS mutant (A) wildtype (B) NSCLC or <br />  Normal Human Bronchial Epithelial (NHBE) cells seeded 96-well plates 24 h. The cells treated various concentrations <br />  (0&#226;&#8364;&#8220;10 &#206;&#188;M) bosutinib 72 h followed cell viability assay measured CellTitre Glo. The cell viability results normalized DMSO-treated <br />  controls expressed percentage. (C) Four NSCLC cells treated bosutinib 72 h different concentrations. Caspase3/7 activities were <br />  measured using Caspase-Glo 3/7 luminescent assay kit. The enzymatic activity expressed value respect untreated cells. <br />  <br />  <br />  <br /> 0.1 &#206;&#188;M, consistent bosutinib-specific &#226;&#8364;&#339;on-target&#226;&#8364;?                           Separately, assembly 210 tumors, we <br /> kinase inhibition clinically relevant doses (Cmax                        created TMAs examine clinical relevance ACK1 <br /> bosutinib 400 mg daily 190 ng/mL approxi-                       expression NSCLC. Here chose focus total <br /> mately 0.3 &#206;&#188;M).                                                                ACK1 expression phospho-ACK1 reasons. <br />   In study, silencing ACK1 SRC signifi-                       First, shown previously cell lines over- <br /> cantly reduced cell migration invasion, confirming                   expression wild type ACK1 plasmid resulted ACK1 <br /> role regulating metastasis. In addition, using bosutinib                    phosphorylated active [17]. Secondly, com- <br /> at dose 0.5 &#206;&#188;M 1 &#206;&#188;M)) chemical probe,                           mercial available phospho-ACK1 antibody optimized <br /> observed effect migration invasion                        TMAs, artefactual dephosphorylation to <br /> abrogated knockdown ACK1 SRC,                               inconsistencies time fixation paraffin embedded <br /> highlighting importance ACK1 signaling axis.                     surgical samples limit accuracy depicting intrin- <br /> This supported zebrafish model,                        sic signaling activity [28,29]. In cohort 210 patients <br /> siRNA ACK1 abrogated anti-migratory effect                           lung adenocarcinoma, substantial and <br /> bosutinib. Another previously reported interacting partner                     significant difference ACK1 protein expression between <br /> of ACK1, AXL shown regulate cell migration                         non-tumor tumor cores, consistent role in <br /> and invasion breast cancer. In NSCLC panel,                          tumorigenesis. However, did clear inverse <br /> found absence AXL NCI-H1792 effect                           association tumor ACK1 over-expression and <br /> on bosutinib-induced inhibition cell migration                          survival, suggesting nuanced relationship clinical <br /> invasion (Additional file 4: Figure S3), suggesting                       outcomes. It possible majority tumours the <br /> contradistinct breast cancer [27]. AXL play                       TMA stage I, ACK1 expression less <br /> dominant role metastatic <span id='am-162' about='Thesaurus:TESSE01' typeof='owl:Thing'><span id='am-163' property="rdfs:label" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-164' property="rdfs:label" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-165' property="Thesaurus:code" content="TEESS18" datatype="rdf:PlainLiteral"></span><span id='am-166' property="Thesaurus:Preferred_Name" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-167' property="rdfs:label" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-168' property="Thesaurus:code" content="TEESS25" datatype="rdf:PlainLiteral"></span><span id='am-169' property="Thesaurus:Preferred_Name" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-170' property="Thesaurus:code" content="TEESS07" datatype="rdf:PlainLiteral"></span><span id='am-171' property="Thesaurus:code" content="TEESS13" datatype="rdf:PlainLiteral"></span><span id='am-172' property="Thesaurus:Preferred_Name" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-173' property="Thesaurus:Preferred_Name" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-174' property="rdfs:label" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-175' property="Thesaurus:Preferred_Name" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-176' property="Thesaurus:code" content="TEESS08" datatype="rdf:PlainLiteral"></span><span id='am-177' property="Thesaurus:code" content="TEESS09" datatype="rdf:PlainLiteral"></span><span id='am-178' property="Thesaurus:code" content="TEESS04" datatype="rdf:PlainLiteral"></span><span id='am-179' property="rdfs:label" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-180' property="Thesaurus:code" content="TEESS22" datatype="rdf:PlainLiteral"></span><span id='am-181' property="Thesaurus:code" content="TEESS02" datatype="rdf:PlainLiteral"></span><span id='am-182' property="Thesaurus:Preferred_Name" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-183' property="Thesaurus:Preferred_Name" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-184' property="rdfs:label" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-185' property="rdfs:label" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-186' property="Thesaurus:code" content="TEESS06" datatype="rdf:PlainLiteral"></span><span id='am-187' property="rdfs:label" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-188' property="Thesaurus:Preferred_Name" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-189' property="Thesaurus:Preferred_Name" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-190' property="Thesaurus:code" content="TEESS15" datatype="rdf:PlainLiteral"></span><span id='am-191' property="rdfs:label" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-192' property="Thesaurus:Preferred_Name" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-193' property="rdfs:label" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-194' property="rdfs:label" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-195' property="rdfs:label" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-196' property="rdfs:label" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-197' property="rdfs:label" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-198' property="Thesaurus:Preferred_Name" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-199' property="Thesaurus:code" content="TEESS10" datatype="rdf:PlainLiteral"></span><span id='am-200' property="Thesaurus:code" content="TEESS17" datatype="rdf:PlainLiteral"></span><span id='am-201' property="Thesaurus:Preferred_Name" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-202' property="Thesaurus:Preferred_Name" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-203' property="Thesaurus:code" content="TEESS19" datatype="rdf:PlainLiteral"></span><span id='am-204' property="Thesaurus:code" content="TEESS05" datatype="rdf:PlainLiteral"></span><span id='am-205' property="Thesaurus:Preferred_Name" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-206' property="rdfs:label" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-207' property="Thesaurus:code" content="TEESS03" datatype="rdf:PlainLiteral"></span><span id='am-208' property="Thesaurus:Preferred_Name" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-209' property="Thesaurus:Preferred_Name" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-210' property="Thesaurus:Preferred_Name" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-211' property="rdfs:label" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-212' property="rdfs:label" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-213' property="rdfs:label" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-214' property="rdfs:label" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-215' property="Thesaurus:code" content="TEESS21" datatype="rdf:PlainLiteral"></span><span id='am-216' property="rdfs:label" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-217' property="Thesaurus:Preferred_Name" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-218' property="rdfs:label" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-219' property="Thesaurus:code" content="TEESS20" datatype="rdf:PlainLiteral"></span><span id='am-220' property="rdfs:label" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-221' property="Thesaurus:code" content="TEESS01" datatype="rdf:PlainLiteral"></span><span id='am-222' property="Thesaurus:code" content="TEESS11" datatype="rdf:PlainLiteral"></span><span id='am-223' property="rdfs:label" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-224' property="Thesaurus:Preferred_Name" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-225' property="Thesaurus:code" content="TEESS24" datatype="rdf:PlainLiteral"></span><span id='am-226' property="Thesaurus:Preferred_Name" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-227' property="Thesaurus:Preferred_Name" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-228' property="Thesaurus:Preferred_Name" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-229' property="Thesaurus:Preferred_Name" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-230' property="rdfs:label" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-231' property="rdfs:label" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-232' property="Thesaurus:Preferred_Name" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-233' property="rdfs:label" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-234' property="Thesaurus:Preferred_Name" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-235' property="Thesaurus:code" content="TEESS12" datatype="rdf:PlainLiteral"></span><span id='am-236' property="Thesaurus:code" content="TEESS14" datatype="rdf:PlainLiteral"></span><span id='am-237' property="Thesaurus:code" content="TEESS23" datatype="rdf:PlainLiteral"></span><span id='am-238' property="Thesaurus:Preferred_Name" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-239' property="Thesaurus:code" content="TEESS16" datatype="rdf:PlainLiteral"></span>phenotype</span> NSCLC.                            impact clinical outcome. In later stage tumours, given <br /> Furthermore, given ACK1 activated re-                           central role ACK1 migration invasion, any <br /> ceptor tyrosine kinases EGFR ALK [5,24],                           increase protein expression, regardless extent, can <br /> bosutinib broader therapeutic relevance                            deleterious &#226;&#8364;&#8220; mitigating correlation between <br /> NSCLC.                                                                         intensity percentage patient outcomes. Intriguingly, <br />  Tan et al. Molecular Cancer 2014, 13:13                                                                                     Page 5 10 <br /> http://www.molecular-cancer.com/content/13/1/13 <br />  <br />  <br />  <br />  <br />                                                                            expression ACK1 paired surrounding adjacent <br />                                                                            &#226;&#8364;&#339;normal&#226;&#8364;? lung tissue associated poor outcome, <br />                                                                            suggesting ACK1 activation early event <br />                                                                            lung cancer carcinogenesis. <br />                                                                               Another interesting observation arising study is <br />                                                                            relationship KRAS, ACK1 cell migration, <br />                                                                            invasion EMT. To date, direct connection <br />                                                                            proteins, exception publication <br />                                                                            Nur et al. [16]. Their work suggested ACK1 is <br />                                                                            important pro-oncogenic factor downstream constitu- <br />                                                                            tive active RAS, probably mediating EMT. Consistent <br />                                                                            notion, numerous reports suggested that <br />                                                                            RAS activation TGF signaling results upregulation <br />                                                                            2 transcription factors, snail snug, repress <br />                                                                            E-cadherin induce EMT [30-32]. Our preliminary <br />                                                                            analysis twist, mesenchymal transcription factor using <br />                                                                            real time PCR panel NSCLC lines showed differ- <br />                                                                            ential high low twist mRNA RAS mutant WT <br />                                                                            cell lines respectively (data shown). <span id='am-2' about='protege:FROM' typeof='owl:Thing'>From</span> panel of <br />                                                                            cell lines, preliminary data suggests RAS-driven EMT <br />                                                                            migratory signals mediated ACK1. <br />                                                                               Recently, phase I study bosutinib, including an <br />                                                                            expansion cohort colon, lung pancreatic cancer, <br />                                                                            reported [20]. Although objective tumor responses <br />                                                                            recorded trial did meet predetermined <br />                                                                            efficacy endpoints, stable disease observed 47% of <br />                                                                            NSCLC patients (n = 19), 16% patients dur- <br />                                                                            able disease control 24 weeks. Regrettably, <br />                                                                            KRAS EGFR status reported study, <br />                                                                            plausible high ACK1 expression stratify <br />                                                                            subgroup EGFR KRAS mutant patients likely to <br />                                                                            respond bosutinib. <br />                                                                               In conclusion, ACK1 inhibition affects cell motility and <br />                                                                            migration particularly context KRAS mutant <br />                                                                            NSCLC cell lines, highly expressed lung adeno- <br />                                                                            carcinoma compared paired surrounding non-tumor <br />                                                                            tissue. Given implicated role ACK-1 EGFR, KRAS <br />                                                                            ALK signaling, suggest potential therapeutic <br />                                                                            niche combination studies bosutinib selecting for <br />                                                                            patients ACK-1 overexpression, specifically circum- <br />  Figure 3 Bosutinib inhibit cell migration invasion ACK1            venting tumor metastasis recurrence. <br />  dependent SRC- independent. NCI-H1792 transfected with <br />  siRNA (control, ACK1 SRC) using Oligofectamine 72 h. The cells     Materials methods <br />  harvested 72 h. (A) Quantitative real-time PCR analysis was <br />                                                                            Lung cancer cell lines <br />  performed using 20 ng cDNA respective primers set ack1 and <br />  src normalized gapdh. The serum-starved cells trypsinized     Human lung adenocarcinoma cell lines [NCI-H1650, NCI- <br />  seeded upper chamber Transwell (8 mm pore, B)            H1792, NCI-H1838, NCI-H1975, NCI-H2009, NCI-H2291, <br />  Matrigel&#226;&#8222;&#162; (C), presence DMSO bosutinib various            NCI-H2444, HCC-95, HCC-193, EKVX SK-Lu-1] were <br />  concentrations (0.5 1 &#206;&#188;M). Medium containing 10% FBS DMSO         provided Max Planck Institute Biochemistry au- <br />  bosutinib (0.5 1 &#206;&#188;M) used chemoattractant lower <br />  chamber. The cells fixed stained 0.5% crystal violet blue <br />                                                                            thenticated using STR profiling John Hopkins Fragment <br />  6 h (migration, B) 24 h (invasion, C). Cells migrated   Analysis Facility (April 2013). All cells maintained in <br />  invaded filter counted. Experiments carried      Roswell Park Memorial Institute medium supplemented <br />  duplicates random fields counted.                            L-glutamine 10% fetal bovine serum, for <br />                                                                            SK-Lu-1 cells maintained Minimum Essen- <br />                                                                            tial Medium L-glutamine 10% fetal bovine serum. <br />  Tan et al. Molecular Cancer 2014, 13:13                                                                                                    Page 6 10 <br /> http://www.molecular-cancer.com/content/13/1/13 <br />  <br />  <br />  <br />  <br />  Figure 4 Reduction lung cancer cell metastasis zebrafish embryos bosutinib ACK1 dependent. Embryo injected Vibrant DiD <br />  labeled NCI-H2009 cells showing tumor foci burden determined segmented red channel (upper) scatter plot representation cell <br />  dissemination (bottom). Each data series represents fish number injected embryos 3 biological replicates indicated (n). Comparative <br />  inhibition cell migration, measured Migration Index, untreated drug pretreated cells represented bar graph (right), <br />  Mean &#194;&#177; SD. (A) Embryos injected NCI-H2009 transfected control siRNA. (B) Embryos injected NCI-H2009 transfected SRC <br />  siRNA. (C) Embryos injected NCI-H2009 transfected ACK1 siRNA. <br />  <br />  <br />  <br /> Normal Human Bronchial Epithelial Cells (NHBE)                           fluoride, 0.2 &#206;&#188;g/ml Aprotinin) 20 minutes 4&#194;&#176;C, and <br /> purchased Lonza (Basel, Switzerland), cultured                       protein concentration measured using BCA protein <br /> in serum-free medium described Clonetics. All cells                     assay (Thermo Scientific, Rockford, IL). Protein samples <br /> were incubated 37&#194;&#176;C incubator 5% CO2.                               subjected SDS-PAGE transferred polyvi- <br />                                                                               nylidene difluoride membrane. Membranes blocked <br /> Reagents                                                                      5% milk PBST/TBST (0.1% Tween-20) incu- <br /> Bosutinib (SKI-606) purchased LC Laboratories                        bated primary antibodies: anti-ACK1 (A-11) <br /> (Woburn, MA) prepared DMSO 10 mM stock.                             antibodies (Santa Cruz Biotechnology, Santa Cruz, CA), anti- <br /> The compound diluted desired concentration                          &#206;&#178;-actin-HRP, anti-GAPDH-HRP, anti-SRC antibodies <br /> culture medium (or DMSO) treatment. Results                            (Cell Signaling Technology&#194;&#174;, Beverly, MA). The secondary <br /> were separately validated bosutinib, synthesized                      antibodies anti-mouse anti-rabbit horseradish <br /> Vichem Chemie Research Ltd (Budapest, Hungary)                                peroxidase conjugated antibodies (GE Healthcare). Detec- <br />                                                                               tion performed using Immobilon Western Chemilu- <br /> Protein extraction Western blot analysis                                  minescence HRP substrate (Millipore, Billerica, MA). <br /> Cells lysed lysis buffer (50 mM HEPES, 150 mM <br /> NaCl, 1 mM EDTA, 10% Glycerin, 1% Triton X-100,                               Cell viability assay <br /> 10 mM Sodium pyrophosphate, 10 mM sodium fluoride,                            Cancer cell lines NHBE cells seeded 96-well <br /> 2 mM sodium orthovanadate, 1 mM phenylmethanesulfonyl                         plates 80% confluency (1000 5000 cells). Cells were <br />  Tan et al. Molecular Cancer 2014, 13:13                                                                                                      Page 7 10 <br /> http://www.molecular-cancer.com/content/13/1/13 <br />  <br />  <br />  <br />  <br />     Figure 5 ACK1 highly expressed lung adenocarcinoma. Immunohistochemistry staining performed 210 NSCLC tumor paired <br />     non-tumor sections in-house TMA using anti-ACK1 (C20, material method). (A) ACK1 immuno-positivity defined presence <br />     brown cytoplasmic staining. Staining intensity scored 0, 1+, 2+ 3+ (no, weak, moderate strong staining, respectively). (B) <br />     Percentage positively stained tumor cells assessed proportion total number tumor cells present section. Intensity percentage <br />     score, IP, defined product maximum immunostaining intensity percentage tumor cells stained. <br />  <br />  <br /> treated various concentrations Bosutinib 72 h.                       8.0 &#206;&#188;m pore polycarbonate membrane insert <br /> Cell viability measured using CellTiter-Glo reagent                          (Corning, Inc., Corning, NY), duplicates. Cell migrated <br /> (Promega, Madison, WI) according manufacturer&#226;&#8364;&#8482;s                               lower chamber containing 600 &#206;&#188;L medium <br /> instructions. Cell viability results normalized                          10% FBS DMSO Bosutinib (0.1, 0.5 and <br /> DMSO-treated controls expressed percentage.                               1 &#206;&#188;M) 6 h. This followed fixation staining with <br />                                                                                  0.5% crystal violet blue 25% methanol. Non-migrating <br /> Apoptotic assay                                                                  cells removed cotton swab migrated cells <br /> Cells seeded 96-well plates 80% confluency                          counted random microscopic fields. Invasion <br /> overnight (1000&#226;&#8364;&#8220;5000 cells) treated Bosutinib                        assay performed migration assay replacing <br /> various concentrations 72 h. Apoptosis measured                          transwell Matrigel&#226;&#8222;&#162; transwells (Corning, Inc., <br /> using Caspase-Glo&#194;&#174; 3/7 luminescent assay according                            Corning, NY). <br /> manufacturer&#226;&#8364;&#8482;s instructions (Promega Corp., Madison, WI). <br /> Caspase activity expressed percentage DMSO                           siRNA silencing <br /> treated cells set 100%.                                                       Cells seeded 24-well plate transfected <br />                                                                                  siRNA ACK1 (#103419), SRC (#683), nega- <br /> Migration invasion assay                                                     tive control (Ambion, Austin, TX) using Oligofectatmine&#226;&#8222;&#162; <br /> Serum-starved cells (50000 100000) suspended                          transfection reagent (Invitrogen, Carlsbad, CA) described <br /> 200 &#206;&#188;L serum-free medium treated Bosutinib                           manufacturer&#226;&#8364;&#8482;s protocol. Cells collected use at <br /> (0.1, 0.5 1 &#206;&#188;M) DMSO control. Cells loaded                           72 h transfection. <br /> Table 1 Unique relationship* overall relapse-free survival ACK1 IP tumor non-tumor tissues <br />                                      Overall survival                                                 Relapse-free survival <br /> Tumor ACK 1 IP                       p = 0.982 (overall) (per 10 units) 0.999 (0.930-1.074)           p = 0.719 (overall) (per 10 units) 0.987 (0.916-1.062) <br /> Non-tumor ACK 1 IP                   p &lt; 0.001 (overall) (per 10 units) 2.002 (1.370-2.927)           p &lt; 0.001 (overall) (per 10 units) 1.907 (1.328-2.737) <br /> * <br /> Adjusted stage grade. <br />  Tan et al. Molecular Cancer 2014, 13:13                                                                           Page 8 10 <br /> http://www.molecular-cancer.com/content/13/1/13 <br />  <br />  <br />  <br />  <br /> Quantitative Real-Time PCR                                       drug treatment imaged using confocal fluorescence <br /> Total RNA extracted purified using RNeasy                microscope (Olympus, FV1200). Multiple Z plane images <br /> Mini Kit (Qiagen, Germantown, MD). Superscript&#226;&#8222;&#162; III              taken embryo composite images made <br /> First-strand synthesis kit ((Invitrogen, Carlsbad, CA)           using ImageJ software. All composite images gathered, <br /> was used reverse transcription manufacturer&#226;&#8364;&#8482;s          aligned specific orientation, analyzed scatter <br /> recommended conditions. Real-time PCR cDNA              plot determine tumor foci position relative injection <br /> product performed Applied Biosystems&#226;&#8364;&#8482;s 7500             site (0,0 graph). Number metastatic tumor cell foci <br /> Fast real-time PCR (Foster City, CA). Primers             positions calculated applying minimum area filter <br /> specific ACK1, SRC GAPDH used               exclude unanchored migrating single cells. Axes rep- <br /> with Fast SYBR&#194;&#174; green master mix (Applied Biosystems,            resent distance (&#206;&#188;m) injection site. Cumu- <br /> Foster City, CA) PCR amplification manufac-            lative distance (CD) traveled metastatic tumor cell foci <br /> turer&#226;&#8364;&#8482;s conditions.                                              (in &#206;&#188;m) calculated graph the <br />                                                                  sum distances identified tumor foci the <br /> Zebrafish metastasis model                                       injection point single embryo. <br /> The zebrafish metastasis model (Zgraft) developed          Migration Index = 1/n &#226;&#710;&#8216;(CD 48 h/Total number of <br /> approved protocols Wayne State University          viable cells 48 h) n number embryos <br /> Institutional Animal Care Use Committee (USA)                considered experiment. <br /> and University Windsor Animal Care Committee,                To quantify surviving tumor cells zebrafish larvae, <br /> Canadian Council Animal Care. Embryos obtained           zebrafish embryos incubated 50 &#206;&#188;l protease <br /> from natural spawnings AB strain. Developmental            solution (2 units/ml collagenase (Roche) 60 units/ml <br /> stages reported hours post-fertilization (hpf) 28&#194;&#176;C.   dispase (Roche) DMEM 2 h 37&#194;&#176;C. Cells were <br />   NCI-H2009 tumor cells, transfected siRNA          gently dispersed pipetting dissociate transplanted <br /> ACK1, SRC, negative control, cultured 37&#194;&#176;C       embryo single cell suspension. 50 &#206;&#188;l 8% parafor- <br /> to 80% confluency, detached using Trypsin-EDTA solution          maldehyde solution added directly wells fix <br /> (Sigma), washed twice DPBS (Gibco, Invitrogen)          count fluorescent cells. <br /> further incubated 20 min 37&#194;&#176;C serum free culture <br /> media containing 0.05% DiD (Vibrant, Invitrogen). After       Clinical data <br /> incubation 20 min, cells washed twice        Cases resected lung adenocarcinoma 10 years <br /> incubated 5 h media containing 0.25 &#206;&#188;M bosutinib.         period retrieved lung cancer database <br /> Cells washed twice re-suspended DPBS in-         maintained National Cancer Centre Singapore. Clinical <br /> jection. 24&#226;&#8364;&#8220;30 hpf zebrafish embryos dechorionated          outcome data including overall relapse-free survival <br /> and anesthetized tricaine (Sigma). Using Nanoject II        collected database. This retrospective out- <br /> (Drummond) injector, 200 cells injected yolk       come data approved Singhealth ethics review <br /> of embryo. After injection, embryos incubated          committee. <br /> for 2 h 31&#194;&#176;C checked successful injection. Em- <br /> bryos fluorescent cells outside yolk sack          Construction tissue microarray (TMA) <br /> excluded experimentation analysis.              Paraffin embedded formalin fixed tissue blocks paired <br /> Injected embryos transferred 96-well plate             slides retrieved reviewed, representative <br /> (one embryo/well) containing Bosutinib (0.25 &#206;&#188;M) diluted         tumor areas selected TMA construction. Selected <br /> in 200 ml E3 media (without methylene blue)          tumor samples punched tissue blocks using <br /> incubated 35&#194;&#176;C 46 h. Control embryos drug         Beecher microarrayer. Briefly, sample one <br /> were treated incubated diluent (DMSO).                morphologically non-tumor area adjacent tumour <br />                                                                  morphologically representative tumor areas were <br /> Quantification cellular migration metastasis              defined based haematoxylin eosin (HE)-stained <br /> in zebrafish                                                     sections. From areas, tissue cylinder was <br /> Cellular migration metastasis xenotransplanted            punched blocks transferred recipi- <br /> tumor cells zebrafish embryos greatly influenced        ent paraffin block. Each cylinder diameter 2.0 mm. <br /> the number cells injected, <span id='am-84' about='Thesaurus:TESSE01' typeof='owl:Thing'><span id='am-85' property="Thesaurus:Preferred_Name" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-86' property="Thesaurus:code" content="TEESS11" datatype="rdf:PlainLiteral"></span><span id='am-87' property="rdfs:label" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-88' property="Thesaurus:code" content="TEESS09" datatype="rdf:PlainLiteral"></span><span id='am-89' property="rdfs:label" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-90' property="Thesaurus:code" content="TEESS24" datatype="rdf:PlainLiteral"></span><span id='am-91' property="Thesaurus:Preferred_Name" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-92' property="Thesaurus:code" content="TEESS19" datatype="rdf:PlainLiteral"></span><span id='am-93' property="rdfs:label" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-94' property="Thesaurus:code" content="TEESS23" datatype="rdf:PlainLiteral"></span><span id='am-95' property="Thesaurus:code" content="TEESS01" datatype="rdf:PlainLiteral"></span><span id='am-96' property="Thesaurus:Preferred_Name" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-97' property="Thesaurus:Preferred_Name" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-98' property="Thesaurus:code" content="TEESS03" datatype="rdf:PlainLiteral"></span><span id='am-99' property="rdfs:label" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-100' property="Thesaurus:Preferred_Name" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-101' property="rdfs:label" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-102' property="Thesaurus:Preferred_Name" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-103' property="Thesaurus:code" content="TEESS02" datatype="rdf:PlainLiteral"></span><span id='am-104' property="Thesaurus:Preferred_Name" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-105' property="Thesaurus:Preferred_Name" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-106' property="Thesaurus:code" content="TEESS25" datatype="rdf:PlainLiteral"></span><span id='am-107' property="Thesaurus:code" content="TEESS12" datatype="rdf:PlainLiteral"></span><span id='am-108' property="Thesaurus:code" content="TEESS05" datatype="rdf:PlainLiteral"></span><span id='am-109' property="rdfs:label" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-110' property="Thesaurus:Preferred_Name" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-111' property="Thesaurus:code" content="TEESS21" datatype="rdf:PlainLiteral"></span><span id='am-112' property="Thesaurus:code" content="TEESS13" datatype="rdf:PlainLiteral"></span><span id='am-113' property="rdfs:label" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-114' property="Thesaurus:Preferred_Name" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-115' property="rdfs:label" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-116' property="rdfs:label" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-117' property="Thesaurus:Preferred_Name" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-118' property="Thesaurus:Preferred_Name" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-119' property="rdfs:label" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-120' property="rdfs:label" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-121' property="rdfs:label" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-122' property="rdfs:label" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-123' property="rdfs:label" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-124' property="Thesaurus:Preferred_Name" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-125' property="rdfs:label" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-126' property="rdfs:label" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-127' property="Thesaurus:Preferred_Name" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-128' property="Thesaurus:code" content="TEESS17" datatype="rdf:PlainLiteral"></span><span id='am-129' property="Thesaurus:Preferred_Name" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-130' property="Thesaurus:Preferred_Name" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-131' property="Thesaurus:Preferred_Name" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-132' property="Thesaurus:code" content="TEESS18" datatype="rdf:PlainLiteral"></span><span id='am-133' property="Thesaurus:code" content="TEESS22" datatype="rdf:PlainLiteral"></span><span id='am-134' property="Thesaurus:code" content="TEESS10" datatype="rdf:PlainLiteral"></span><span id='am-135' property="Thesaurus:code" content="TEESS07" datatype="rdf:PlainLiteral"></span><span id='am-136' property="Thesaurus:Preferred_Name" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-137' property="rdfs:label" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-138' property="rdfs:label" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-139' property="rdfs:label" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-140' property="Thesaurus:Preferred_Name" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-141' property="Thesaurus:Preferred_Name" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-142' property="Thesaurus:code" content="TEESS06" datatype="rdf:PlainLiteral"></span><span id='am-143' property="rdfs:label" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-144' property="Thesaurus:code" content="TEESS20" datatype="rdf:PlainLiteral"></span><span id='am-145' property="rdfs:label" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-146' property="Thesaurus:Preferred_Name" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-147' property="Thesaurus:Preferred_Name" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-148' property="Thesaurus:Preferred_Name" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-149' property="rdfs:label" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-150' property="Thesaurus:code" content="TEESS15" datatype="rdf:PlainLiteral"></span><span id='am-151' property="Thesaurus:Preferred_Name" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-152' property="Thesaurus:code" content="TEESS08" datatype="rdf:PlainLiteral"></span><span id='am-153' property="Thesaurus:Preferred_Name" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-154' property="Thesaurus:Preferred_Name" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-155' property="rdfs:label" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-156' property="rdfs:label" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-157' property="rdfs:label" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-158' property="Thesaurus:code" content="TEESS16" datatype="rdf:PlainLiteral"></span><span id='am-159' property="Thesaurus:code" content="TEESS04" datatype="rdf:PlainLiteral"></span><span id='am-160' property="Thesaurus:code" content="TEESS14" datatype="rdf:PlainLiteral"></span><span id='am-161' property="rdfs:label" content="Targeted mutation" datatype="rdf:PlainLiteral"></span>cell survival</span> drug <br /> treatment, time incubation post injection. For        Immunohistochemistry <br /> consistent quantitative comparison cellular migration         4 mm sections cut TMA blocks fished <br /> between different tumor cell lines different drug treat-     coated slides (POLYSINE, Menzel-glaser) similar <br /> ments, Migration Index calculated analysis         orientation facilitate evaluation. Sections stained <br /> performed microscopic imaging. Embryos               anti-ACK1 antibody using optimized protocols. Briefly, <br /> anesthetized microscope slide 48 h post injection        paraffin sections formalin-fixed tissue stained for <br />  Tan et al. Molecular Cancer 2014, 13:13                                                                                                                  Page 9 10 <br /> http://www.molecular-cancer.com/content/13/1/13 <br />  <br />  <br />  <br />  <br /> ACK1 using anti-ACK (sc-323 Santa Cruz Biotechnology)                                  Additional file 4: Figure S3. Bosutinib inhibition cell migration is <br /> with 1:100 dilution. Sections pretreated citrate                               AXL independent. (A) 50 &#206;&#188;g lysate protein analyzed total AXL protein <br /> buffer (pH 6.0) 110&#194;&#176;C 15 minutes pressure                                using Western blot. 500 &#206;&#188;g individual lysate immunoprecipitated <br />                                                                                        anti-AXL (AF154) immunoblot antiphosphotyrosine (4G10). <br /> cooker. The staining Dako Autostainer plus                               The PVDF membrane stripped re-blotted anti-AXL (C-20). <br /> (Dako Colorado, Inc., USA) fully automated immuno-                                (B) NCI-H1792 transfected siRNA using Oligofectamine 72 h. <br /> histochemical staining visualization Dako REAL&#226;&#8222;&#162;                                 The serum starved cells trysinized seeded upper chamber <br />                                                                                        Transwell (8 &#206;&#188;m pore), presence DMSO bosutinib at <br /> EnVision&#226;&#8222;&#162; Detection System (K5007). A breast cancer                                    various concentrations. Medium containing 10% FBS DMSO bosutinib <br /> section used positive control according antibody                             used chemoattractant lower chamber. Cells fixed and <br /> data sheet.                                                                            stained 0.5% crystal violet blue 6 h. Cells migrated the <br />                                                                                        filter counted. Experiments carried duplicates five <br />    Stained slides scanned using ScanScope digital                                 random fields counted. Knockdown confirmed western blot analysis <br /> scanners (Aperio, Vista, CA). Scanned slides                                 50 &#206;&#188;g total protein right. <br /> viewed scored using Aperio Image Scope deter- <br /> mine intensity immunostaining. ACK1 immunopositiv-                              Abbreviations <br /> ity defined presence brown cytoplasmic staining.                         ACK1: Activated Cdc42 associated kinase 1; UBA: Ubiquitin association <br /> Staining intensity scored 0, 1+, 2+ 3+ (no, weak,                       domain; EGFR: Epidermal growth factor receptor; RCC: Renal clear cell <br />                                                                                    carcinoma; EMT: Epithelial-mesenchymal transition; TNF: Tumor necrosis <br /> moderate strong staining, respectively). Percentage                         factor; HSP60: Heat shock protein 60. <br /> positively stained tumor cells assessed proportion <br /> of total number tumor cells present section. In-                         Competing interests <br /> tensity percentage score (IP) documented. Intensity                           All authors declare conflict interest. <br /> percentage score defined product maximum <br /> immunostaining intensity percentage tumor cells                             Authors&apos; contributions <br /> stained. Staining scored independently certi-                          DSW provided managed clinical samples. BH performed the <br />                                                                                    statistical analysis. JMT SCT did cell-based experiments. IS and <br /> fied pathologists (Dr Lim KH Dr Takano A).                                     HPL set zebrafish metastasis assay analysed data. SSK and <br />                                                                                    MMMT performed histological sectioning IHC staining AT and <br />                                                                                    HKL provided professional pathological assessment staining. EHT and <br /> Statistical analysis                                                               WTL provided clinical input advises. The work performed <br />                                                                                    support AU EHT. The manuscript drafted DSW and <br /> Tumor non-tumor ACK1 immunohistochemistry                                      BTC. All authors read approved final manuscript. <br /> measures compared using paired t-tests. Overall <br /> and relapse-free survival compared context                             Acknowledgements <br /> of Cox proportional hazards models, individually                              This work supported Biomedical Research council (BMRC) Agency <br /> and adjusting important covariates stage                         Science Technology Research (ASTAR) National Cancer Centre <br />                                                                                    Singapore. This work funded National Medical Research <br /> grade. Analysis performed R statistical software.                           Council Grant (NMRC/1224/2009), National Cancer Centre Research Fund <br /> Data preclinical experiments analysed                                (NRFMP10111-10112). We grateful Trailblazer Foundation Ltd. <br /> presented using Graphpad Prism version 6.0c.                                       instrumental support Lung Cancer Consortium Singapore <br />                                                                                    (NRFTB11122). <br />  <br />                                                                                    Author details <br /> Additional files                                                                   1 <br />                                                                                     Department Medical Oncology, National Cancer Centre Singapore, <br />                                                                                    Singapore, Singapore. 2Cancer Therapeutics Research Laboratory, National <br />  Additional file 1: Figure S1. Bosutinib inhibit cell migration                Cancer Centre Singapore, Singapore, Singapore. 3Centre Quantitative <br />  invasion ACK1 dependent SRC independent. SK-Lu-1                      Medicine, Office Clinical Sciences, Duke-NUS Graduate Medical School, <br />  transfected various siRNA using Oligofectamines harvested                Singapore, Singapore. 4Department Statistics Applied Probability, <br />  72 h. (A) Quantitative real time PCR analysis performed using              National University Singapore, Singapore, Singapore. 5Singapore <br />  20 ng cDNA respective primer set ack1 src normalized               OncoGenome Laboratory, Institute Medical Biology, Agency Science <br />  gapdh. The serum-starved cells trysinized seeded                  Technology Research, Singapore, Singapore. 6Biomedcore Inc., 1580 <br />  upper chamber Transwells (8 &#206;&#188;m pore, B) MatrixgelTM(C),              Rossi Drive, Tecumseh ON N9A 6 J3, Canada. 7Department Pathology, <br />  presence DMSO 0.5 &#206;&#188;M bosutinib. Medium containing                    Singapore General Hospital, Singapore, Singapore. 8p53 Laboratory, <br />  10% FBS DMSO bosutinib (0.5 &#206;&#188;M) used chemoattractant             Biomedical Science Institutes Agency Science Technology Research, <br />  lower chamber. Cells fixed stained 0.5% crystal violet blue     Singapore, Singapore. 9Max-Planck Institute Biochemistry, Am Klopferspitz, <br />  6 h (migration, B) 24 h (invasion, C). Cells migrated   Martinsried, Germany. 10INM-SOG, Institute Molecular Cell Biology, <br />  filter counted. Experiments carried duplicates         Agency Science Technology Research, Singapore, Singapore. <br />  random fields counted. <br />                                                                                    Received: 24 September 2013 Accepted: 21 January 2014 <br />  Additional file 2: FigureS2. Real time PCR analysis ACK1 SRC.               Published: 24 January 2014 <br />  NCI-H2009 transfected siRNA (control, ACK1 SRC) using <br />  Oligofectamine 72 h. The cells harvested 72 h. Quantitative <br />  real-time PCR analysis performed using 20 ng cDNA respective           References <br />  primers set ack1 src normalized gapdh.                             1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer <br />  Additional file 3: Table S1. Individual relationships OS RFS               statistics. CA Cancer J Clin 2011, 61:69&#226;&#8364;&#8220;90. <br />                                                                                    2. Li T, Kung H-J, Mack PC, Gandara DR: Genotyping genomic profiling <br />  clinical variables ACK1 measures tumor paired <br />  non-tumor tissues.                                                                    non-small-cell lung cancer: implications current future therapies. <br />                                                                                        J Clin Oncol 2013, 31:1039&#226;&#8364;&#8220;1049. <br />  Tan et al. Molecular Cancer 2014, 13:13                                                                                                                   Page 10 10 <br /> http://www.molecular-cancer.com/content/13/1/13 <br />  <br />  <br />  <br />  <br /> 3.    Tan DSW, Gerlinger M, Teh BT, Swanton C: Anti-cancer drug resistance:           23. Liu Z, Adams HC, Whitehead IP: The rho-specific guanine nucleotide <br />       understanding mechanisms use integrative genomics                exchange factor Dbs regulates breast cancer cell migration. J Biol Chem <br />       functional <span id='am-318' about='Thesaurus:TESSE01' typeof='owl:Thing'><span id='am-319' property="Thesaurus:code" content="TEESS07" datatype="rdf:PlainLiteral"></span><span id='am-320' property="rdfs:label" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-321' property="Thesaurus:Preferred_Name" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-322' property="Thesaurus:Preferred_Name" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-323' property="Thesaurus:Preferred_Name" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-324' property="Thesaurus:code" content="TEESS12" datatype="rdf:PlainLiteral"></span><span id='am-325' property="rdfs:label" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-326' property="Thesaurus:code" content="TEESS10" datatype="rdf:PlainLiteral"></span><span id='am-327' property="Thesaurus:Preferred_Name" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-328' property="Thesaurus:Preferred_Name" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-329' property="Thesaurus:Preferred_Name" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-330' property="Thesaurus:code" content="TEESS20" datatype="rdf:PlainLiteral"></span><span id='am-331' property="rdfs:label" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-332' property="Thesaurus:Preferred_Name" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-333' property="rdfs:label" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-334' property="rdfs:label" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-335' property="Thesaurus:Preferred_Name" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-336' property="Thesaurus:code" content="TEESS02" datatype="rdf:PlainLiteral"></span><span id='am-337' property="Thesaurus:Preferred_Name" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-338' property="Thesaurus:Preferred_Name" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-339' property="Thesaurus:code" content="TEESS11" datatype="rdf:PlainLiteral"></span><span id='am-340' property="rdfs:label" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-341' property="Thesaurus:code" content="TEESS15" datatype="rdf:PlainLiteral"></span><span id='am-342' property="rdfs:label" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-343' property="rdfs:label" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-344' property="rdfs:label" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-345' property="Thesaurus:code" content="TEESS25" datatype="rdf:PlainLiteral"></span><span id='am-346' property="rdfs:label" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-347' property="Thesaurus:code" content="TEESS17" datatype="rdf:PlainLiteral"></span><span id='am-348' property="Thesaurus:code" content="TEESS06" datatype="rdf:PlainLiteral"></span><span id='am-349' property="rdfs:label" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-350' property="rdfs:label" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-351' property="Thesaurus:Preferred_Name" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-352' property="Thesaurus:Preferred_Name" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-353' property="Thesaurus:code" content="TEESS08" datatype="rdf:PlainLiteral"></span><span id='am-354' property="rdfs:label" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-355' property="Thesaurus:code" content="TEESS05" datatype="rdf:PlainLiteral"></span><span id='am-356' property="Thesaurus:code" content="TEESS18" datatype="rdf:PlainLiteral"></span><span id='am-357' property="Thesaurus:Preferred_Name" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-358' property="rdfs:label" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-359' property="rdfs:label" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-360' property="Thesaurus:Preferred_Name" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-361' property="Thesaurus:code" content="TEESS13" datatype="rdf:PlainLiteral"></span><span id='am-362' property="rdfs:label" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-363' property="Thesaurus:Preferred_Name" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-364' property="Thesaurus:Preferred_Name" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-365' property="rdfs:label" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-366' property="Thesaurus:code" content="TEESS14" datatype="rdf:PlainLiteral"></span><span id='am-367' property="Thesaurus:Preferred_Name" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-368' property="Thesaurus:code" content="TEESS19" datatype="rdf:PlainLiteral"></span><span id='am-369' property="Thesaurus:Preferred_Name" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-370' property="rdfs:label" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-371' property="Thesaurus:code" content="TEESS21" datatype="rdf:PlainLiteral"></span><span id='am-372' property="Thesaurus:Preferred_Name" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-373' property="rdfs:label" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-374' property="Thesaurus:Preferred_Name" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-375' property="Thesaurus:code" content="TEESS23" datatype="rdf:PlainLiteral"></span><span id='am-376' property="rdfs:label" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-377' property="rdfs:label" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-378' property="Thesaurus:code" content="TEESS24" datatype="rdf:PlainLiteral"></span><span id='am-379' property="rdfs:label" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-380' property="Thesaurus:Preferred_Name" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-381' property="rdfs:label" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-382' property="Thesaurus:code" content="TEESS16" datatype="rdf:PlainLiteral"></span><span id='am-383' property="rdfs:label" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-384' property="Thesaurus:code" content="TEESS22" datatype="rdf:PlainLiteral"></span><span id='am-385' property="rdfs:label" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-386' property="Thesaurus:code" content="TEESS01" datatype="rdf:PlainLiteral"></span><span id='am-387' property="Thesaurus:Preferred_Name" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-388' property="Thesaurus:code" content="TEESS04" datatype="rdf:PlainLiteral"></span><span id='am-389' property="Thesaurus:Preferred_Name" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-390' property="Thesaurus:code" content="TEESS09" datatype="rdf:PlainLiteral"></span><span id='am-391' property="Thesaurus:Preferred_Name" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-392' property="Thesaurus:Preferred_Name" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-393' property="rdfs:label" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-394' property="Thesaurus:code" content="TEESS03" datatype="rdf:PlainLiteral"></span><span id='am-395' property="Thesaurus:Preferred_Name" content="Mutation analysis" datatype="rdf:PlainLiteral"></span>RNA interference</span>. Eur J Cancer 2010, 46:2166&#226;&#8364;&#8220;2177.                   2009, 284:15771&#226;&#8364;&#8220;15780. <br /> 4.    Manser E, Leung T, Salihuddin H, Tan L, Lim L: A non-receptor tyrosine          24. Pao-Chun L, Chan PM, Chan W, Manser E: Cytoplasmic ACK1 interaction <br />       kinase inhibits GTPase activity p21cdc42. Nature 1993,                  multiple receptor tyrosine kinases mediated Grb2: analysis <br />       363:364&#226;&#8364;&#8220;367.                                                                        ACK1 effects Axl signaling. J Biol Chem 2009, 284:34954&#226;&#8364;&#8220;34963. <br /> 5.    Kato-Stankiewicz J, Ueda S, Kataoka T, Kaziro Y, Satoh T: Epidermal growth      25. Konantz M, Balci TB, Hartwig UF, Dellaire G, Andr&#195;&#169; MC, Berman JN, Lengerke <br />       factor stimulation ACK1/Dbl pathway Cdc42 Grb2-dependent            C: Zebrafish xenografts tool vivo studies human cancer. <br />       manner. Biochem Biophys Res Commun 2001, 284:470&#226;&#8364;&#8220;477.                               Ann N Y Acad Sci 2012, 1266:124&#226;&#8364;&#8220;137. <br /> 6.    Teo M, Tan L, Lim L, Manser E: The tyrosine kinase ACK1 associates         26. Roberts PJ, Stinchcombe TE: KRAS <span id='am-240' about='Thesaurus:TESSE01' typeof='owl:Thing'><span id='am-241' property="rdfs:label" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-242' property="rdfs:label" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-243' property="rdfs:label" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-244' property="Thesaurus:code" content="TEESS14" datatype="rdf:PlainLiteral"></span><span id='am-245' property="rdfs:label" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-246' property="rdfs:label" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-247' property="Thesaurus:Preferred_Name" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-248' property="Thesaurus:code" content="TEESS11" datatype="rdf:PlainLiteral"></span><span id='am-249' property="Thesaurus:code" content="TEESS09" datatype="rdf:PlainLiteral"></span><span id='am-250' property="rdfs:label" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-251' property="Thesaurus:Preferred_Name" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-252' property="Thesaurus:Preferred_Name" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-253' property="rdfs:label" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-254' property="Thesaurus:Preferred_Name" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-255' property="Thesaurus:code" content="TEESS15" datatype="rdf:PlainLiteral"></span><span id='am-256' property="Thesaurus:code" content="TEESS17" datatype="rdf:PlainLiteral"></span><span id='am-257' property="Thesaurus:code" content="TEESS22" datatype="rdf:PlainLiteral"></span><span id='am-258' property="Thesaurus:code" content="TEESS05" datatype="rdf:PlainLiteral"></span><span id='am-259' property="Thesaurus:code" content="TEESS13" datatype="rdf:PlainLiteral"></span><span id='am-260' property="Thesaurus:Preferred_Name" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-261' property="Thesaurus:Preferred_Name" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-262' property="Thesaurus:code" content="TEESS24" datatype="rdf:PlainLiteral"></span><span id='am-263' property="Thesaurus:code" content="TEESS10" datatype="rdf:PlainLiteral"></span><span id='am-264' property="Thesaurus:code" content="TEESS21" datatype="rdf:PlainLiteral"></span><span id='am-265' property="rdfs:label" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-266' property="Thesaurus:Preferred_Name" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-267' property="rdfs:label" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-268' property="rdfs:label" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-269' property="rdfs:label" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-270' property="Thesaurus:Preferred_Name" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-271' property="Thesaurus:Preferred_Name" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-272' property="Thesaurus:code" content="TEESS07" datatype="rdf:PlainLiteral"></span><span id='am-273' property="rdfs:label" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-274' property="rdfs:label" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-275' property="Thesaurus:code" content="TEESS18" datatype="rdf:PlainLiteral"></span><span id='am-276' property="Thesaurus:code" content="TEESS03" datatype="rdf:PlainLiteral"></span><span id='am-277' property="Thesaurus:code" content="TEESS16" datatype="rdf:PlainLiteral"></span><span id='am-278' property="Thesaurus:Preferred_Name" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-279' property="Thesaurus:Preferred_Name" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-280' property="Thesaurus:Preferred_Name" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-281' property="rdfs:label" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-282' property="rdfs:label" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-283' property="rdfs:label" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-284' property="Thesaurus:Preferred_Name" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-285' property="Thesaurus:Preferred_Name" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-286' property="Thesaurus:code" content="TEESS06" datatype="rdf:PlainLiteral"></span><span id='am-287' property="rdfs:label" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-288' property="rdfs:label" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-289' property="Thesaurus:code" content="TEESS04" datatype="rdf:PlainLiteral"></span><span id='am-290' property="Thesaurus:code" content="TEESS20" datatype="rdf:PlainLiteral"></span><span id='am-291' property="Thesaurus:Preferred_Name" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-292' property="rdfs:label" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-293' property="rdfs:label" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-294' property="rdfs:label" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-295' property="Thesaurus:Preferred_Name" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-296' property="Thesaurus:Preferred_Name" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-297' property="Thesaurus:Preferred_Name" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-298' property="Thesaurus:code" content="TEESS01" datatype="rdf:PlainLiteral"></span><span id='am-299' property="rdfs:label" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-300' property="Thesaurus:Preferred_Name" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-301' property="Thesaurus:Preferred_Name" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-302' property="Thesaurus:Preferred_Name" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-303' property="Thesaurus:code" content="TEESS25" datatype="rdf:PlainLiteral"></span><span id='am-304' property="Thesaurus:Preferred_Name" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-305' property="Thesaurus:code" content="TEESS02" datatype="rdf:PlainLiteral"></span><span id='am-306' property="rdfs:label" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-307' property="rdfs:label" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-308' property="Thesaurus:Preferred_Name" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-309' property="Thesaurus:Preferred_Name" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-310' property="Thesaurus:code" content="TEESS08" datatype="rdf:PlainLiteral"></span><span id='am-311' property="Thesaurus:Preferred_Name" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-312' property="Thesaurus:code" content="TEESS19" datatype="rdf:PlainLiteral"></span><span id='am-313' property="Thesaurus:code" content="TEESS23" datatype="rdf:PlainLiteral"></span><span id='am-314' property="rdfs:label" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-315' property="rdfs:label" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-316' property="Thesaurus:Preferred_Name" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-317' property="Thesaurus:code" content="TEESS12" datatype="rdf:PlainLiteral"></span>Mutation</span>: Should We Test It, and <br />       clathrin-coated vesicles binding motif shared arrestin             Does It Matter? J Clin Oncol 2013, 31:1112&#226;&#8364;&#8220;1121. <br />       adaptors. J Biol Chem 2001, 276:18392&#226;&#8364;&#8220;18398.                              27. Zhang Y-X, Knyazev PG, Cheburkin YV, Sharma K, Knyazev YP, Orfi L, Szabadkai I, <br /> 7.    Shen F, Lin Q, Gu Y, Childress C, Yang W: Activated Cdc42-associated                Daub H, K&#195;&#169;ri G, Ullrich A: AXL potential target therapeutic intervention <br />       kinase 1 component EGF receptor signaling complex regulates             breast cancer progression. Cancer Res 2008, 68:1905&#226;&#8364;&#8220;1915. <br />       EGF receptor degradation.  <br /> </body></html>